TrialThe British journal of dermatology2020

A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.

A Blauvelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.